Denali Therapeutics Inc.（纳斯达克代码：DNLI）近日宣布，将在2026年世界研讨会上展示其酶转运载体技术平台在亨特综合征、A型桑菲利波综合征以及庞贝病治疗领域的多项研究数据。
此次公布的数据将涵盖临床前及早期临床研究结果，重点展示酶转运载体技术在突破血脑屏障、提升治疗效率方面的潜力。三项罕见病治疗项目均采用公司独创的酶转运载体技术，旨在通过增强酶替代疗法的靶向性，改善药物在中枢神经系统的分布效果。
公司表示，这些数据的发布将为进一步推进罕见病治疗方案的临床开发提供重要科学依据。世界研讨会作为罕见病研究领域的国际权威会议，此次成果展示也将为行业专家评估酶转运载体技术的应用前景提供关键参考。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.